Medical/Pharmaceuticals

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

* OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab * New anatomic data demonstrates OLN324 achieves faster, greater, and more durable re...

2026-03-31 08:00 5019

4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union

In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging s...

2026-03-31 05:20 4818

Sanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence

SHANGHAI, March 30, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals has recently been honored as a "Shanghai Municipal Enterprise Technology Center" in recognition of its outstanding technological innovation capabilities, comprehensive R&D infrastructure, sustained investment in innovation, and r...

2026-03-30 22:00 6374

Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today a...

2026-03-30 21:53 9773

Tigermed Announces 2025 Annual Results

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...

2026-03-30 20:56 6681

EDAN Launches EDAN Nano OB Assist, an AI-Enabled Handheld Ultrasound, to Expand Access to Prenatal Screening in Africa

NAIROBI, Kenya, March 30, 2026 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a global medical device company, announced the launch of EDAN Nano OB Assist, an AI-enabled handheld ultrasound system designed to expand access to essential prenatal screening in ...

2026-03-30 20:55 4004

CGBIO Showcases Minimally Invasive Spine Surgery Techniques in Thailand: "Smaller Incisions, Faster Recovery"

* Korea–Thailand spine experts jointly lead advanced training on endoscopic spine surgery and lateral lumbar interbody fusion techniques * Hands-on experience with Korean spine medical devices lays the foundation for advancing Asia's spine education hub SEOUL, South Korea and BANGKOK, March 3...

2026-03-30 20:00 4812

CELEBRATING 25 YEARS AND BEYOND OF LIFE AFTER ORGAN TRANSPLANTATION AT THE NATIONAL UNIVERSITY CENTRE FOR ORGAN TRANSPLANTATION

Honouring 35 patients who stand as inspiring examples of resilience, underscoring the long-term success of organ transplantation SINGAPORE, March 30, 2026 /PRNewswire/ -- For transplant recipients, reaching the 25-year mark is a significant achievement. According to international statistics, a d...

2026-03-30 19:43 4589

IFPA launches first Africa Forum on psoriasis calling for urgent action on overlooked disease

Nairobi event takes place May 7-9 STOCKHOLM, March 30, 2026 /PRNewswire/ -- IFPA (The International Federation of Psoriasis Associations) – is convening the first-ever regional summit dedicated exclusively to psoriasis in Africa - one of the continent's most underrecognized chronic diseases. ...

2026-03-30 18:00 4724

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won"Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been...

2026-03-30 13:33 6539

Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year

TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximately RMB714 million, a 6.75-fold increase year-on-year. Pr...

2026-03-30 12:39 8190

AROA Biosurgery Completes Randomised Controlled Trial for Symphony™; Preliminary Read-Out indicates Primary Endpoint Met

AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and ...

2026-03-30 09:59 5364

Insilico Medicine Announces Global R&D Collaboration with Lilly

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. CAMBRIDGE, Mass., March 29, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial in...

2026-03-30 08:30 6011

Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants

SYDNEY, March 30, 2026 /PRNewswire/ -- Organon Asia Pacific Cluster today announced the 2026 Her Health Grant recipients for the Asia Pacific region, marking a significant milestone in efforts to strengthen and expand women's health initiatives across the region. The Her Health Grants are design...

2026-03-30 06:31 4734

Foshan Launches First Provincial-Level International Medical Pilot

Foshan Fosun Chancheng Hospital Sets New Benchmark for Greater Bay Area Healthcare FOSHAN, China, March 29, 2026 /PRNewswire/ -- On March 28, Foshan Fosun Chancheng Hospital inaugurated the International Medical Center (FIMC), Foshan's first provincial-level international medical pilot, supporti...

2026-03-29 14:54 4756

Better by MTA Expands Its Global Elite Network with Distinguished New Platinum Members

PALM BEACH GARDENS, Fla., March 27, 2026 /PRNewswire/ -- Better by MTA, the premier global platform connecting medical travelers with trusted facilitators and accredited healthcare providers, proudly announces the addition of distinguished new Platinum Members. These leaders in international hosp...

2026-03-27 22:40 5484

Akeso Reports Full-Year 2025 Financial Results

HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business. Commercial Operations Enter a New Phase of Growth In 2025, Akeso achieved record ...

2026-03-27 11:54 8252

Zimmer Biomet Wins Three Awards at Healthcare Asia Medtech Awards 2026

Awards Recognize Innovations in Infection Measures, AI-Driven Recovery and Surgeon Engagement across Asia Pacific. SINGAPORE, March 27, 2026 /PRNewswire/ -- Zimmer Biomet (NYSE and SIX: ZBH), a global medical technology leader, today announced it received three awards at the Healthcare Asia Medt...

2026-03-27 08:30 5542

Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million

CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), a commercial-stage biopharmaceutical company dedicated t...

2026-03-26 22:08 6518

CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

Rapid Advancement Across Core R&D Pipeline * The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an excellent...

2026-03-26 21:32 11654
1 ... 35363738394041 ... 649